The accreditation, which followed a routine re-audit in November, is the first positive news for the plant since the US Food and Drug Administration (FDA) imposed an import ban and halted its review of all drugs made there earlier this year.
While the Therapeutic Goods Administration (TGA) approval is limited to the sale of drugs in Australia, clearance from the Medicines and Healthcare products Regulatory agency (MHRA) enables Ranbaxy to sell medicines in both the UK and Europe under the regions mutual recognition procedure.